The French National Agency for Medicines and Health Products Safety (ANSM) has announced the closure of its national pharmacovigilance investigation into mRNA vaccines against Covid-19, after five years of enhanced monitoring. Surveillance continues, however, through regional centers, and the agency reaffirms that recent data confirm the safety of the Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) vaccines.
Reports covering February 2024 to June 2025 revealed no new safety signals. For Comirnaty, the analysis of 21 cases deemed sensitive—including, in particular, ocular disorders, inflammatory syndromes, and neurological diseases—established no link with the vaccination. The conclusions are identical for Spikevax; the five cases studied (including two cases of ALS and one case of dermatomyositis) showed no association with the vaccine.
The ANSM (French National Agency for Medicines and Health Products Safety) emphasizes that it now has unprecedented experience, with over 160 million doses administered in France and billions worldwide, without any new risks emerging. It also points out that an Epi-Phare study published in JAMA Network Open observed no increase in mortality in France since the introduction of the vaccines, despite claims circulating in some skeptical circles.
 Sophie de Duiéry
|
16/03/2026 | 
| 
Anglais
Français
Español
Italien
Português